TNF and inflammatory bowel disease: Reasons for discontinuation of TNF-α blocking therapy were inefficacy (n = 17; 44%), adverse events (n = 11; 28%: diarrhea or inflammatory bowel disease (IBD; n = 4); infection (n = 3); allergic reaction (n = 2); cardio-vascular disease (n = 1); demyelization problems (n = 1)), both inefficacy and adverse events (n = 5; 13%: diarrhea or IBD (n = 2); infection (n = 1); allergic reaction (n = 1); uveitis (n = 1)), or other reasons (n = 6; 15%: good initial response, own choice (n = 3); pregnancy wish (n = 2); lost to follow-up (n = 1)).